Company intelligence / Profile preview

Panex

Ownership: Private
Employees: ~2
Development stage: Other

Overview

Pannex Therapeutics is developing first-in-class small molecule blockers of the Pannexin 1 channel, aiming to deliver safer and more effective treatments for chronic pain, opioid addiction prevention, and select cancers such as TNBC; efficacy demonstrated in preclinical models, no human clinical results yet disclosed

Therapeutic areas: OncologyNeurologyPsychiatry
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Panex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Panex.

Explore the full profile